https://www.selleckchem.com/products/torin-1.html
G protein-coupled estrogen receptor 30 (GPR3 activation by its agonist, G1, exhibits beneficial actions in female with heart failure (HF). Recent evidence indicates its cardiovascular benefits may also include male as well. However, whether and how GPR30 activation may limit HF progression and have a salutary role in males is unknown. We hypothesized that chronic G1 treatment improves LV and cardiomyocyte function, [Ca ] regulation and β-adrenergic reserve, thus limiting HF progression in male. We compared left ventricle (LV) and myoc
Like
Comment
Share
